The evaluation of the plasma levels of interleukin 17A, thymic stromal lymphopoietin, interferon gamma, tumor necrosis factor-alpha and interleukins IL-2, IL-6, IL-23, and IL-31 in atopic dermatitis patients with dupilumab treatment

Dupilumab effectively suppresses Th2 signaling but does not fully normalize immune balance<b>;</b> residual Th17 and innate activity persists. Elevated TSLP and IL-6 suggest that epithelial stress and innate immune activation remain key drivers. Reduced IL-23 and IL-2 under stimulation indicate altered adaptive immune responsiveness in AD patients.